Anavex is one of only three Phase 3 trial top line results being presented at CTAD. The biggest AD clinical trial conference of the year. Every attendee focusing their careers on AD will attend every one of these rubber meets the road presentations, along with every stock analyst specializing in that space. Success with Sigma 1 agonist will be the end of their amyloid focused careers and they know it.
News 
Market Data 
Discover 
